Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy's Laboratories Stock Down 0.5 %
Dr. Reddy's Laboratories stock traded down $0.26 during mid-day trading on Tuesday, reaching $52.91. The company's stock had a trading volume of 130,758 shares, compared to its average volume of 192,049. The company has a market capitalization of $8.81 billion, a price-to-earnings ratio of 22.61 and a beta of 0.46. Dr. Reddy's Laboratories has a 12 month low of $47.88 and a 12 month high of $67.76. The business's 50 day simple moving average is $54.70 and its 200 day simple moving average is $54.57. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.41 and a current ratio of 1.98.
Dr. Reddy's Laboratories (NYSE:RDY - Get Rating) last released its earnings results on Thursday, May 19th. The company reported $0.53 earnings per share for the quarter. The business had revenue of $717.00 million during the quarter. Dr. Reddy's Laboratories had a net margin of 13.63% and a return on equity of 18.61%. As a group, research analysts anticipate that Dr. Reddy's Laboratories will post 2.56 earnings per share for the current year.
Dr. Reddy's Laboratories Increases Dividend
The company also recently disclosed an annual dividend, which was paid on Monday, July 11th. Stockholders of record on Monday, July 11th were given a $0.325 dividend. This represents a dividend yield of 0.58%. The ex-dividend date of this dividend was Friday, July 8th. This is an increase from Dr. Reddy's Laboratories's previous annual dividend of $0.29. Dr. Reddy's Laboratories's dividend payout ratio (DPR) is 13.68%.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on RDY shares. Barclays increased their target price on shares of Dr. Reddy's Laboratories from $69.00 to $70.00 and gave the stock an "overweight" rating in a report on Tuesday, May 24th. StockNews.com upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, June 23rd. Finally, TheStreet lowered shares of Dr. Reddy's Laboratories from a "b" rating to a "c+" rating in a report on Friday, July 22nd.